Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Lars Tramsen"'
Publikováno v:
Frontiers in Immunology, Vol 8 (2017)
Invasive fungal infections are still an important cause of morbidity and mortality in immunocompromised patients such as patients suffering from hematological malignancies or patients undergoing hematopoietic stem cell transplantion. In addition, oth
Externí odkaz:
https://doaj.org/article/e48bc36773d84667947e2f8de869bfff
Publikováno v:
Antimicrobial Agents and Chemotherapy. 63
Despite the availability of new antifungal compounds, invasive aspergillosis carries high morbidity and mortality in hematopoietic stem cell transplant recipients. In vitro studies and animal models suggest that the adoptive transfer of natural kille
Publikováno v:
Antimicrobial agents and chemotherapy. 63(2)
Despite the availability of new antifungal compounds, invasive aspergillosis carries high morbidity and mortality in hematopoietic stem cell transplant recipients. In vitro studies and animal models suggest that the adoptive transfer of natural kille
Publikováno v:
Frontiers in Immunology
Frontiers in Immunology, Vol 8 (2017)
Frontiers in Immunology, Vol 8 (2017)
Invasive fungal infections are still an important cause of morbidity and mortality in immunocompromised patients such as patients suffering from hematological malignancies or patients undergoing hematopoietic stem cell transplantion. In addition, oth
Autor:
Ralf Schubert, Thomas Lehrnbecher, Ada Balan, Özer Degistirici, Stanislaw Schmidt, Andreas Schneider, Lars Tramsen, Roland Meisel
Publikováno v:
Oncotarget
Mesenchymal stromal cells (MSCs) are increasingly given as immunotherapy to hematopoietic stem cell transplant (HSCT) recipients with refractory graft-versus-host disease (GvHD). Whereas the immunosuppressive properties of MSCs seem to be beneficial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff11ed9f8d7f5f7e06aae8586fcb618a
http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/45182
http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/45182
Publikováno v:
Mycoses. 57:8-12
Summary Mucormycoses remain a serious complication in patients undergoing allogeneic haematopoietic stem cell transplantation (HSCT). In these patients, mortality rates of mucormycosis reach up to 90%, which is due, at least in part, to the severe an
Autor:
Stanislaw Schmidt, Thomas Lehrnbecher, Emilia Salzmann-Manrique, Thomas Klingebiel, Jean-Paul Latgé, Frauke Roeger, Lars Tramsen, Ralf Schubert
Publikováno v:
Infection and Immunity. 82:2649-2656
Allogeneic hematopoietic stem cell transplant (HSCT) recipients are at high risk for invasive aspergillosis. Whereas adoptive immunotherapy transferring donor-derived anti- Aspergillus T H 1 cells has been shown to be beneficial for HSCT recipients s
Autor:
Peter Bader, Ada Balan, Stanislaw Schmidt, Lars Tramsen, Andreas Schneider, Roland Meisel, Selim Kuçi, Thomas Lehrnbecher, G Lucchini
Publikováno v:
Leukemia. 28:1941-1948
Mesenchymal stromal cells (MSCs) are multipotent cells, which exhibit broad immunosuppressive activities. Moreover, they may be administered irrespectively of human leukocyte antigen (HLA) compatibility, without inducing life-threatening immunologica
Autor:
Susanne Perkhofer, Stanislaw Schmidt, Frauke Röger, Thomas Klingebiel, Thomas Lehrnbecher, Mitra Hanisch, Lars Tramsen, Cornelia Lass-Flörl, Ulrike Koehl
Publikováno v:
Immunobiology. 218:939-944
Mucormycosis has a high mortality and is increasingly diagnosed in hematopoietic stem cell transplant (HSCT) recipients. In this setting, there is a growing interest to restore host defense to combat infections by adoptively transferring donor-derive
Autor:
Lars Tramsen, Dirk Reinhardt, Thomas Klingebiel, Emilia Salzmann-Manrique, Ursula Creutzig, Konrad Bochennek, Lillian Sung, Thomas Lehrnbecher
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 34(23)
Purpose Although nonpharmacologic anti-infective measures are widely used in children treated for acute myeloid leukemia (AML), there is little evidence of their effectiveness. Patients and Methods We analyzed infectious complications in children dur